Rapport Therapeutics (RAPP) Return on Capital Employed (2024 - 2026)
Rapport Therapeutics' (RAPP) quarterly Return on Capital Employed came in at 25.09% in Q1 2026, up 603.0% year-on-year from 3.57% in Q1 2025, and down 1.24% on a QoQ basis from 24.78% in Q4 2025.
Rapport Therapeutics (RAPP) Return on Capital Employed (2024 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 3 years of Return on Capital Employed data on file, last reported at 25.09% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 603.0% year-over-year to 25.09% in Q1 2026; TTM through Mar 2026 was 25.09%, a 603.0% increase from a year earlier, with the FY2025 full-year figure at 31.7%, up 498.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 25.09%, down from 24.78% in the prior quarter.
- Over the last five years, Return on Capital Employed for RAPP reached as high as 22.42% in Q3 2024 and fell as low as 36.1% in Q2 2025.
- Historically, Return on Capital Employed has averaged 27.68% across 3 years, with a median of 26.43% in 2024.
- Across the five-year window, Return on Capital Employed sank 538 bps in 2025 and soared 603 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 26.43% in 2024, then advanced by 6 bps to 24.78% in 2025, then decreased by 1 bps to 25.09% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 25.09% in Q1 2026, 24.78% in Q4 2025, and 27.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Rapport Therapeutics | 1.95 Bn | 1.95 Bn | - | -25.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.09% |
| Dec 31, 2025 | -24.78% |
| Sep 30, 2025 | -27.80% |
| Jun 30, 2025 | -36.10% |
| Mar 31, 2025 | -31.12% |
| Dec 31, 2024 | -26.43% |
| Sep 30, 2024 | -22.42% |